Xbrane Biopharma AB (OSTO:XBRANE) Margin of Safety % (DCF Earnings Based) : N/A (As of Jun. 06, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xbrane Biopharma AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based) falls into.

Xbrane Biopharma AB Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines